0001225208-20-007336.txt : 20200508 0001225208-20-007336.hdr.sgml : 20200508 20200508191738 ACCESSION NUMBER: 0001225208-20-007336 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200507 FILED AS OF DATE: 20200508 DATE AS OF CHANGE: 20200508 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MUSSALLEM MICHAEL A CENTRAL INDEX KEY: 0001204551 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-15525 FILM NUMBER: 20862213 MAIL ADDRESS: STREET 1: C/O EDWARDS LIFESCIENCES CORP STREET 2: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Edwards Lifesciences Corp CENTRAL INDEX KEY: 0001099800 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 364316614 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 BUSINESS PHONE: 9492502500 MAIL ADDRESS: STREET 1: ONE EDWARDS WAY CITY: IRVINE STATE: CA ZIP: 92614 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP. DATE OF NAME CHANGE: 20090225 FORMER COMPANY: FORMER CONFORMED NAME: EDWARDS LIFESCIENCES CORP DATE OF NAME CHANGE: 20000203 FORMER COMPANY: FORMER CONFORMED NAME: CVG CONTROLLED INC DATE OF NAME CHANGE: 19991126 4 1 doc4.xml X0306 4 2020-05-07 0001099800 Edwards Lifesciences Corp EW 0001204551 MUSSALLEM MICHAEL A ONE EDWARDS WAY IRVINE CA 92614 1 1 Chairman & CEO Common Stock 2020-05-07 4 A 0 7075.0000 0.0000 A 44200.8200 D Common Stock 2020-05-08 4 M 0 32850.0000 35.7850 A 77050.8200 D Common Stock 2020-05-08 4 S 0 300.0000 221.5800 D 76750.8200 D Common Stock 2020-05-08 4 S 0 2900.0000 218.5400 D 73850.8200 D Common Stock 2020-05-08 4 S 0 5548.0000 217.7800 D 68302.8200 D Common Stock 2020-05-08 4 S 0 6604.0000 220.8600 D 61698.8200 D Common Stock 2020-05-08 4 S 0 7498.0000 220.1000 D 54200.8200 D Common Stock 2020-05-08 5 G 0 10000.0000 0.0000 D 44200.8200 D Common Stock 2020-05-08 5 G 0 10000.0000 0.0000 A 891194.0000 I By Living Trust Common Stock 123918.8025 I 401(k) Employee Stock Option (Right to Acquire) 218.0400 2020-05-07 4 A 0 70700.0000 0.0000 A 2020-06-07 2027-05-06 Common Stock 70700.0000 70700.0000 D Performance Rights 2020-05-07 4 A 0 8825.0000 0.0000 A 2023-05-07 2027-05-06 Common Stock 8825.0000 8825.0000 D Employee Stock Option (Right to Acquire) 35.7850 2020-05-08 4 M 0 32850.0000 0.0000 D 2013-06-14 2020-05-13 Common Stock 32850.0000 0.0000 D These restricted stock units were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on April 26, 2019. This transaction was executed in multiple trades at prices ranging from $221.46 to $221.81. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $218.24 to $219.23. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $217.22 to $218.14. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $220.43 to $221.39. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. This transaction was executed in multiple trades at prices ranging from $219.43 to $220.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares and prices at which the transaction was effected. Shares represented on the most recent statement of Issuer's 401(k) Plan Administrator. These options were granted on May 7, 2020 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one month after the grant date in 36 approximately equal monthly installments. Reflects the target number of shares (the Target Award) covered by restricted stock units granted under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program on May 7, 2020 and scheduled to vest on May 7, 2023. The number of restricted stock units that vest will depend upon achievement of certain performance goals over a three-year performance period and will range from 0% to 175% of the Target Awards. This Form 4 reflects changes in beneficial ownership only; it does not identify other securities of the Issuer beneficially owned by the Reporting Person. Linda J. Park, Attorney-in-Fact 2020-05-08